Patent: 9,839,646

Summary for Patent: 9,839,646

Title:	Small molecule enhancer for dendritic cell cancer vaccines
Abstract:	Disclosed is a method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases. Also disclosed is a method of (a) increasing antitumor immunity, (b) stimulating or enhancing an immune response, (c) treating a condition characterized by abnormal cell proliferation, (d) increasing cytokine and/or chemokine production, or (e) stimulating or enhancing production of T-cells, in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases. For example, the compound that inhibits a plurality of mammalian DASH serine proteases may be t-butylGly-boroPro.
Inventor(s):	Bachovchin; William W. (Cambridge, MA)
Assignee:	Trustees of Tufts College (Boston, MA)
Application Number:	14/948,777
Patent Claims:	see list of patent claims

Details for Patent 9,839,646

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2031-11-22
Clinigen, Inc.	PROLEUKIN	aldesleukin	For Injection	103293	05/05/1992		2031-11-22
Servier Pharmaceuticals Llc	ONCASPAR	pegaspargase	Injection	103411	02/01/1994		2031-11-22
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2031-11-22
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2031-11-22
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2031-11-22
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2031-11-22